Clinical Implications of Anti-Phospholipid Antibodies: The Utah Experience

Publisher Website
Google Scholar
Abstract
In the summer of 1983, we recognized our first patient with fetal loss associated with anti-phospholipid antibodies (aPL). She had three previous second trimester fetal deaths and a deep venous thrombosis complicating one of her pregnancies. Only a few weeks later, Lubbe and colleagues reported that fetal death in women with aPL might be avoided by treatment with corticosteroids and low-dose aspirin.1 As obstetricians, we were intrigued by the discovery of a new “cause” of pregnancy loss, especially a potentially treatable one, and we began searching in earnest for patients whose pregnancy loss might be due to aPL.

This publication has 1 reference indexed in Scilit: